Why Bloodwork Matters on Peptide Protocols
Peptides are not supplements. BPC-157 and TB-500 interact with growth hormone pathways, inflammatory signaling, and vascular remodeling — all of which show up in your bloodwork before they show up as symptoms. Coaches who run protocols without a baseline panel are making decisions in the dark.
Bloodwork serves three functions: it establishes the baseline you're measuring against, it catches early signals before they become problems, and it gives you the quantitative proof that the protocol is working. An athlete who feels "better" is anecdote. An athlete whose hs-CRP dropped from 3.8 to 1.1 in six weeks is data.
The monitoring framework below covers which markers to track, what they're looking for, and exactly when to test. It applies to both BPC-157 and TB-500, with peptide-specific additions for each.
Core Biomarker Panel — Every Peptide Protocol
These markers apply regardless of which peptide your athlete is running. Order this full panel at baseline and at week 8. Use the week-4 check for the targeted peptide-specific markers only.
IGF-1 (Insulin-like Growth Factor 1)
BPC-157 up-regulates GH receptor expression, which amplifies the tissue response to growth hormone. That signal flows through IGF-1. Baseline IGF-1 tells you where your athlete sits on the GH axis before you introduce a compound that affects it. Tracking it at week 4 and week 8 shows whether the mechanism is actually engaging.
Why it matters: IGF-1 is the downstream effector of growth hormone. A BPC-157 protocol that isn't moving IGF-1 at all may not be working — or your athlete's GH axis was already saturated. Elevated IGF-1 above range warrants dose reduction.
Liver Enzymes — ALT and AST
ALT (alanine aminotransferase) and AST (aspartate aminotransferase) are the standard markers for hepatic stress. Most peptides in the BPC-157 and TB-500 class are not hepatotoxic, but any protocol involving frequent injections, concurrent supplement use, or stacking with SARMs or oral compounds warrants liver monitoring.
Flag threshold: ALT or AST above 3× the upper limit of normal (typically >120 U/L) is a stop signal. Values between 1.5–3× normal warrant a retest at 2 weeks and removal of any concurrent compounds first.
Kidney Function — BUN and Creatinine
BUN (blood urea nitrogen) and creatinine assess renal filtration capacity. Strength athletes naturally run higher creatinine due to muscle mass — this is not pathological, but it establishes the individual's baseline. Track to ensure no upward trend across the protocol cycle.
The BUN/creatinine ratio provides additional information: a ratio above 20 in a well-hydrated athlete can indicate increased protein catabolism or decreased renal perfusion. Neither is expected from peptide use, but it's worth knowing.
Inflammatory Markers — hs-CRP and ESR
High-sensitivity C-reactive protein (hs-CRP) and erythrocyte sedimentation rate (ESR) measure systemic inflammatory load. These are the two markers where TB-500 protocols should show the most movement — its primary mechanism is anti-inflammatory cytokine modulation.
Baseline context: Most strength athletes with chronic training stress will present with hs-CRP between 1.0–3.0 mg/L. An hs-CRP above 3.0 mg/L at baseline is evidence of significant systemic inflammation and justifies the TB-500 protocol. A baseline below 1.0 mg/L means there's less inflammation to address — adjust expectations accordingly.
Complete Blood Count (CBC)
CBC captures red blood cell count, white blood cell count, hemoglobin, hematocrit, and platelet count. TB-500 influences cell migration and has documented effects on angiogenesis — meaning it touches vascular biology. Tracking hematocrit and hemoglobin across a TB-500 cycle catches any unexpected erythropoietic activity early.
WBC differential (neutrophils, lymphocytes, monocytes) gives additional signal on immune activation. Significant shifts in lymphocyte or monocyte counts warrant investigation.
Thyroid Panel — TSH, Free T3, Free T4
The thyroid panel isn't directly tied to BPC-157 or TB-500 mechanisms, but it belongs in every athlete's baseline for two reasons. First, thyroid dysfunction is common in overtrained athletes and can confound recovery outcomes. Second, the GH axis (which BPC-157 affects) interacts with thyroid function at the hypothalamic level. A suppressed TSH or low Free T3 at baseline explains a lot of "why isn't this working" conversations six weeks later.
Get the Free Bloodwork Reference Card for Coaches
Printable reference card with all 30+ biomarkers, target ranges, and flag thresholds for peptide protocols. Download free.
BPC-157 Specific Markers
On top of the core panel, add these when running BPC-157:
GH (Growth Hormone) — Fasted Morning Draw
BPC-157's primary mechanism is up-regulation of GH receptor expression. A fasted morning GH draw (the natural peak) gives you a proxy for GH axis activity. This is harder to interpret than IGF-1 due to GH's pulsatile secretion, but it's useful context — particularly if your athlete is also running a GH secretagogue (CJC-1295, Ipamorelin) alongside BPC-157.
VEGF (Vascular Endothelial Growth Factor)
VEGF drives angiogenesis — the formation of new blood vessels at injury sites. BPC-157 promotes VEGF expression as part of its tissue repair mechanism. Serum VEGF isn't a standard panel item (it's expensive and not widely ordered), but it's worth including in a baseline panel for athletes on a formal research protocol or when you want mechanistic confirmation. Rising VEGF at week 4 is a signal that the angiogenic mechanism is engaging.
Gut-Related Markers — Calprotectin and Zonulin
BPC-157 has documented effects on gut barrier integrity and GI tract repair. For athletes using BPC-157 specifically for GI indications (suspected leaky gut, NSAID-induced damage, IBS), add fecal calprotectin and serum zonulin to the baseline panel. Calprotectin measures intestinal inflammation; zonulin is a marker of intestinal permeability. If you're running BPC-157 for gut repair, these are the markers that tell you whether it's working.
TB-500 Specific Markers
TB-500's systemic anti-inflammatory mechanism warrants additional monitoring beyond the core panel:
Inflammatory Cytokines — IL-6 and TNF-alpha
TB-500 directly modulates IL-6 and TNF-alpha expression. These are the cytokines behind chronic systemic inflammation in athletes. While hs-CRP is a good proxy (it's cheap and widely available), ordering serum IL-6 and TNF-alpha at baseline and week 8 gives you mechanistic confirmation that TB-500 is hitting its target pathway. An IL-6 that doesn't move across the protocol cycle is useful information — it might mean the inflammation is driven by a different pathway.
Cardiac Markers — Troponin I and BNP
TB-500 has documented cardiac tissue repair effects. For athletes with any history of cardiac stress — hypertrophic cardiomyopathy, elevated blood pressure, prior cardiac events — add troponin I and BNP (B-type natriuretic peptide) to the baseline panel. Troponin I is a sensitive marker of myocardial stress; BNP reflects ventricular workload and cardiac remodeling.
These markers are not expected to move dramatically on a standard TB-500 protocol, but elevated baseline values warrant physician review before starting any compound that affects cardiac biology.
Iron Panel — Serum Iron, Ferritin, TIBC
TB-500 influences cell migration and is being studied in the context of hematopoietic tissue. Track a full iron panel (serum iron, ferritin, total iron-binding capacity) at baseline. Ferritin functions as both an iron storage marker and an acute-phase reactant — it will rise with inflammation and fall as inflammatory load decreases. Tracking ferritin across a TB-500 cycle provides a secondary inflammatory signal alongside hs-CRP.
Testing Frequency
| Timepoint | Panel | Notes |
|---|---|---|
| Baseline (before first dose) |
Full core panel + peptide-specific markers | Establishes your reference point. Do not start protocol without this. |
| Week 4 | hs-CRP, ALT/AST, CBC, IGF-1 | Early safety check + first efficacy signal. Adjust dose if ALT/AST elevated. |
| Week 8 | Full core panel + peptide-specific markers | Primary efficacy assessment. Compare directly to baseline. Decision point for extending or cycling off. |
| Maintenance (if continuing) |
Core panel every 8–12 weeks | Ongoing monitoring for long-term protocols. Full panel recommended at least quarterly. |
How to Read Results — Reference Ranges Coaches Need
| Marker | OK Range | Watch | Flag / Stop |
|---|---|---|---|
| IGF-1 | 100–300 ng/mL (age-adjusted) | >350 ng/mL | >400 ng/mL — reduce BPC-157 dose |
| ALT | 7–56 U/L | 56–120 U/L — retest in 2 weeks | >120 U/L — stop all compounds, physician review |
| AST | 10–40 U/L | 40–80 U/L — retest in 2 weeks | >80 U/L — stop all compounds, physician review |
| Creatinine | 0.7–1.3 mg/dL (athletes may run higher) | Upward trend >0.3 mg/dL from baseline | >1.6 mg/dL or rising trend — physician review |
| hs-CRP | <1.0 mg/L (low risk) 1.0–3.0 mg/L (moderate) |
3.0–10.0 mg/L | >10.0 mg/L — rule out acute infection before attributing to training |
| Hematocrit | 38–50% (M), 35–45% (F) | 50–52% (M) | >52% — assess hydration, rule out erythrocytosis |
| TSH | 0.4–4.0 mIU/L | <0.4 or >4.0 | Persistent suppression or elevation — physician review before continuing |
| Troponin I | <0.04 ng/mL | 0.04–0.12 ng/mL | >0.12 ng/mL — stop TB-500, physician review immediately |
| IL-6 | <3.0 pg/mL | 3.0–10.0 pg/mL | >10.0 pg/mL — significant systemic inflammation, physician review |
| Ferritin | 12–300 ng/mL (varies by sex) | Rising above 300 on TB-500 protocol | >500 ng/mL — rule out hemochromatosis, inflammatory causes |
Lab Ranges Are Population Averages
Standard reference ranges are built from general populations — not strength athletes with elevated muscle mass, high training volume, and optimized recovery protocols. An athlete's "normal" creatinine or CK will run higher than the printed range. This is why baseline data matters more than any single lab value.
Always compare your athlete's results to their own baseline, not just the printed reference range.
Red Flags — When to Stop or Adjust the Protocol
Stop the Protocol Immediately If:
ALT or AST > 3× upper limit of normal — Hepatic stress signal. Remove all compounds, retest in 2 weeks, physician review before resuming anything.
Troponin I > 0.12 ng/mL — Cardiac stress marker. Stop TB-500. Physician evaluation same day.
Serum creatinine rising >0.4 mg/dL above baseline — Renal function change. Stop protocol, increase hydration, physician review.
hs-CRP > 10 mg/L — Rule out acute infection before continuing. Acute infection during a peptide protocol warrants a pause.
Hematocrit > 52% (males) — Assess erythrocytosis workup. Do not add any other compounds until resolved.
Adjust Protocol (Don't Stop) If:
- IGF-1 rising above 350 ng/mL — Reduce BPC-157 dose by 25–30%. Retest in 4 weeks.
- ALT/AST between 1.5–3× normal — Remove any concurrent compounds (SARMs, orals, supplements with hepatic load). Retest in 2 weeks before any dose change.
- hs-CRP not moving after 8 weeks of TB-500 — Reassess root cause. May need to address diet, sleep, or infection load before peptides can show effect.
- TSH out of range at baseline — Address thyroid status with physician before starting protocol. GH axis interventions on a poorly controlled thyroid will produce unpredictable results.
- Hematocrit trending up but below 52% — Increase hydration, reduce BPC-157 dose if co-running with GH secretagogues, retest in 4 weeks.
Putting It Together: The Monitoring Framework
Here's the practical workflow. Before dose one: draw the full baseline panel. Keep a copy. At week 4: draw the short panel (hs-CRP, ALT/AST, CBC, IGF-1). Compare to baseline — if any value is outside the "OK" column above, address it before continuing. At week 8: draw the full panel again. Set it side-by-side with your baseline. This is your efficacy readout.
The markers that should move on a working protocol:
- BPC-157: IGF-1 trending up (if below mid-range at baseline), hs-CRP down, gut markers improving if gut was the indication
- TB-500: hs-CRP down significantly, IL-6 down, ESR down, CBC stable or improved
If none of the efficacy markers moved after 8 weeks at standard dose, the protocol isn't working. The data tells you that — not the athlete's self-report.
For tracking stacked protocols (BPC-157 + TB-500 together), see the peptide stacking guide for how the monitoring framework adjusts when running both simultaneously.
Disclaimer
This article is educational content for licensed coaches and informed athletes. Peptide availability and legality vary by jurisdiction. All protocols and lab interpretations should be reviewed by a qualified physician. Reference ranges provided are general guidance — individual clinical context determines actual interpretation.
Track All of This in Apex
30+ biomarkers, automatic HIGH/LOW flags, trend charts across your protocol timeline. Every marker in this guide is built into Apex's bloodwork module.